To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group. n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##

Provided are compounds and compositions for prevention and/or elimination of Zika virus infection. Also provided are methods for preventing and treating a subject in need of prevention or treatment of Zika virus. The compounds of the present disclosure have the following structure: ##STR00001##

Provided are compounds and compositions for prevention and/or elimination of Zika virus infection. Also provided are methods for preventing and treating a subject in need of prevention or treatment of Zika virus. The compounds of the present disclosure have the following structure: ##STR00001##

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

##STR00001##

For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

##STR00001##

For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

To provide an excellent light emitting material. A compound represented by the following general formula is used as the light emitting material. R is a hydrogen atom, a deuterium atom, an aryl group, or a heteroaryl group bonding via a carbon atom, Ar is an aryl group, or a heteroaryl group bonding via a carbon atom, D.sup.1 and D.sup.2 each are a donor group, and at least one is a hetero ring-condensed carbazol-9-yl group.

##STR00001##

The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I):

##STR00001##

[wherein R.sup.1 is C.sub.1-C.sub.8 alkyl or the like; and R.sup.2-R.sup.9 is hydrogen, halogen, hydroxyl, or Q-(C.sub.1-C.sub.8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.

The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I):

##STR00001##

[wherein R.sup.1 is C.sub.1-C.sub.8 alkyl or the like; and R.sup.2-R.sup.9 is hydrogen, halogen, hydroxyl, or Q-(C.sub.1-C.sub.8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.